## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.1% in lower entry zone (3.0-6.0%), top 4% cross-sectional ranking. Short-term MRS_5 (0.8%) confirms momentum alignment. Outperforming sector by 4.2%. Caution: overbought RSI (73).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($493.09)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Osaic Holdings Inc. Raises Stake in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251219T100903 | Neutral | Relevance: 100%
- Osaic Holdings Inc. significantly increased its stake in United Therapeutics Corporation, purchasing an additional 33,662 shares to hold a total of 46,082 shares valued at approximately $14.03 million. Despite bullish analyst ratings with a consensus "Moderate Buy" and an average target price of $505, there has been substantial insider selling, with major dispositions by a director and the CFO reducing their positions. Institutional ownership accounts for 94.08% of the company's stock, and United Therapeutics reported stronger-than-expected Q3 earnings.

**2. Squarepoint Ops LLC Reduces Stake in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251218T180903 | Neutral | Relevance: 100%
- Squarepoint Ops LLC significantly reduced its stake in United Therapeutics Corporation by 38.1% in Q2, selling 5,145 shares. Despite this, analysts largely maintain a "Moderate Buy" rating with an average target of $505, and some firms have even raised their price targets. Company insiders have also been net sellers, with the COO Michael Benkowitz selling 22,500 shares for over $9 million.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 25 ($16.15M) |
| Sells | 67 ($38.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $39M sold (67 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 18.2x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($38.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.4B |
| Beta | 0.86 |
| 52W Range | $266.98 - $518.61 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 18.2 |
| Current P/E | 19.1 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.8% over 5 days). Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 95th percentile. MRS_5 at 0.8% confirms short-term momentum alignment. Outperforming sector by 4.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.69), confirming momentum. RSI overbought at 73, risk of mean reversion. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.10% (CS: 96) | Strong |
| RSI_14 | 73.1 | Overbought |
| MACD Histogram | 1.69 | Bullish |
| vs SMA20 | 1.058x | Above |
| vs SMA50 | 1.118x | Above |
| vs SMA200 | 1.444x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $517.13
- **Stop Loss:** $493.09 (4.6% risk)
- **Target:** $553.19 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $25,339.37
- **Portfolio %:** 25.34%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*